All In Biotech

Drug Trial Radar · NCT01384734

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose

Last checked: Nov 19, 2026Latest source record: Nov 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Jul 26, 2011

Primary completion

Feb 18, 2013

Study completion May 12, 2017

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jun 29, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • BMS-663068 400 mgDrug

    Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • BMS-663068 800 mgDrug

    Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • BMS-663068 600 mgDrug

    Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • BMS-663068 1200 mgDrug

    Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Raltegravir 400 mgDrug

    Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tenofovir 300 mgDrug

    Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Ritonavir 100 mgDrug

    Tablets, Oral, 100 mg, Once daily, 96 weeks

  • Atazanavir 300 mgDrug

    Capsules, Oral, 300 mg, Once daily, 96 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24Time frame: Week 24
  2. Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24Time frame: Up to Week 24

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Longview, Texas

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Córdoba, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    Bogotá, Colombia

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    München, Germany

  • GSK Investigational Site

    Bonn, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Aguascalientes, Mexico

  • GSK Investigational Site

    DF, Mexico

  • GSK Investigational Site

    Distrito Federal, Mexico

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Guadalajara, Jalisco, Mexico

  • GSK Investigational Site

    Zapopan, Jalisco, Mexico

  • GSK Investigational Site

    San Luis Potosí City, San Luis Potosí, Mexico

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Iquitos, Loreto, Peru

  • GSK Investigational Site

    Bucharest, Romania

  • GSK Investigational Site

    Constanța, Romania

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.